RenovaCare, Inc. (RCAR)
USD 0.0
(-50.0%)
USD 0.0
(-50.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | - USD | 100.0% |
| 2021 | -4.46 Million USD | 52.6% |
| 2020 | -9.41 Million USD | -180.5% |
| 2019 | -3.35 Million USD | -58.34% |
| 2018 | -2.12 Million USD | 42.51% |
| 2017 | -3.68 Million USD | -77.55% |
| 2016 | -2.07 Million USD | -57.59% |
| 2015 | -1.31 Million USD | 38.14% |
| 2014 | -2.13 Million USD | -106.37% |
| 2013 | -1.03 Million USD | -323.34% |
| 2012 | -243.95 Thousand USD | -105.47% |
| 2011 | 4.45 Million USD | 204.48% |
| 2010 | -4.26 Million USD | -436.07% |
| 2009 | 1.26 Million USD | 578.81% |
| 2008 | -265.14 Thousand USD | -974.26% |
| 2007 | -24.68 Thousand USD | 45.16% |
| 2006 | -45 Thousand USD | 33.78% |
| 2005 | -67.96 Thousand USD | 61.17% |
| 2004 | -175.05 Thousand USD | 74.99% |
| 2003 | -699.82 Thousand USD | -166.7% |
| 2002 | -262.4 Thousand USD | 17.47% |
| 2001 | -317.96 Thousand USD | 58.79% |
| 2000 | -771.54 Thousand USD | -8.72% |
| 1999 | -709.65 Thousand USD | -206.05% |
| 1998 | -231.87 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q2 | - USD | 0.0% |
| 2023 Q1 | - USD | 0.0% |
| 2022 FY | - USD | 100.0% |
| 2022 Q3 | 1.07 Million USD | 144.67% |
| 2022 Q1 | -1.72 Million USD | -28.52% |
| 2022 Q4 | - USD | -100.0% |
| 2022 Q2 | -2.41 Million USD | -39.76% |
| 2021 Q4 | -1.34 Million USD | 20.85% |
| 2021 Q1 | -517.24 Thousand USD | 79.67% |
| 2021 Q3 | -1.69 Million USD | -86.22% |
| 2021 Q2 | -911.96 Thousand USD | -76.31% |
| 2021 FY | -4.46 Million USD | 52.6% |
| 2020 Q2 | -3.01 Million USD | -156.36% |
| 2020 Q4 | -2.54 Million USD | 9.72% |
| 2020 FY | -9.41 Million USD | -180.5% |
| 2020 Q3 | -2.81 Million USD | 6.43% |
| 2020 Q1 | -1.17 Million USD | 0.04% |
| 2019 Q3 | -1.11 Million USD | -103.84% |
| 2019 Q2 | -547.5 Thousand USD | -5.44% |
| 2019 Q4 | -1.17 Million USD | -5.31% |
| 2019 FY | -3.35 Million USD | -58.34% |
| 2019 Q1 | -519.26 Thousand USD | 6.94% |
| 2018 FY | -2.12 Million USD | 42.51% |
| 2018 Q3 | -449.58 Thousand USD | 3.42% |
| 2018 Q2 | -465.47 Thousand USD | 28.29% |
| 2018 Q4 | -557.98 Thousand USD | -24.11% |
| 2018 Q1 | -649.14 Thousand USD | 34.8% |
| 2017 Q4 | -995.69 Thousand USD | -16.94% |
| 2017 FY | -3.68 Million USD | -77.55% |
| 2017 Q3 | -851.44 Thousand USD | 32.98% |
| 2017 Q2 | -1.27 Million USD | -122.16% |
| 2017 Q1 | -571.82 Thousand USD | -22.44% |
| 2016 Q2 | -527.35 Thousand USD | 32.47% |
| 2016 Q4 | -467 Thousand USD | -54.31% |
| 2016 Q3 | -302.63 Thousand USD | 42.61% |
| 2016 Q1 | -780.89 Thousand USD | -44.52% |
| 2016 FY | -2.07 Million USD | -57.59% |
| 2015 Q3 | -297.03 Thousand USD | -37.56% |
| 2015 Q1 | -265.19 Thousand USD | -4.47% |
| 2015 Q2 | -215.93 Thousand USD | 18.58% |
| 2015 FY | -1.31 Million USD | 38.14% |
| 2015 Q4 | -540.34 Thousand USD | -81.92% |
| 2014 Q1 | -268.02 Thousand USD | 64.41% |
| 2014 FY | -2.13 Million USD | -106.37% |
| 2014 Q4 | -253.84 Thousand USD | 80.1% |
| 2014 Q3 | -1.27 Million USD | -282.35% |
| 2014 Q2 | -333.68 Thousand USD | -24.5% |
| 2013 Q3 | -184.86 Thousand USD | -121.77% |
| 2013 FY | -1.03 Million USD | -323.34% |
| 2013 Q2 | -83.35 Thousand USD | -296.28% |
| 2013 Q4 | -753.02 Thousand USD | -307.34% |
| 2013 Q1 | -21.03 Thousand USD | 52.44% |
| 2012 FY | -243.95 Thousand USD | -105.47% |
| 2012 Q2 | -77.93 Thousand USD | 6.38% |
| 2012 Q1 | -83.25 Thousand USD | -112.51% |
| 2012 Q3 | -38.53 Thousand USD | 50.56% |
| 2012 Q4 | -44.23 Thousand USD | -14.78% |
| 2011 Q2 | 2.76 Million USD | 2059.23% |
| 2011 Q1 | -141.07 Thousand USD | 97.24% |
| 2011 Q3 | 1.16 Million USD | -57.7% |
| 2011 Q4 | 665.43 Thousand USD | -43.09% |
| 2011 FY | 4.45 Million USD | 204.48% |
| 2010 FY | -4.26 Million USD | -436.07% |
| 2010 Q4 | -5.11 Million USD | -613.96% |
| 2010 Q1 | -2.02 Million USD | -164.29% |
| 2010 Q2 | 1.88 Million USD | 192.88% |
| 2010 Q3 | 995.81 Thousand USD | -47.14% |
| 2009 Q4 | -767.35 Thousand USD | -155.8% |
| 2009 Q3 | 1.37 Million USD | 148.38% |
| 2009 Q2 | 553.61 Thousand USD | 538.24% |
| 2009 Q1 | -126.32 Thousand USD | -3.7% |
| 2009 FY | 1.26 Million USD | 578.81% |
| 2008 FY | -265.14 Thousand USD | -974.26% |
| 2008 Q1 | -14.54 Thousand USD | -123.89% |
| 2008 Q2 | -16.99 Thousand USD | -16.82% |
| 2008 Q4 | -121.81 Thousand USD | -8.96% |
| 2008 Q3 | -111.79 Thousand USD | -558.02% |
| 2007 Q2 | -8250.00 USD | -49.75% |
| 2007 Q4 | -6496.00 USD | -46.74% |
| 2007 Q3 | -4427.00 USD | 46.34% |
| 2007 FY | -24.68 Thousand USD | 45.16% |
| 2007 Q1 | -5509.00 USD | -152.47% |
| 2006 Q1 | -9700.00 USD | 65.89% |
| 2006 FY | -45 Thousand USD | 33.78% |
| 2006 Q4 | 10.5 Thousand USD | 159.1% |
| 2006 Q3 | -17.76 Thousand USD | 36.64% |
| 2006 Q2 | -28.03 Thousand USD | -189.05% |
| 2005 Q1 | -5738.00 USD | -296.31% |
| 2005 Q2 | -10.22 Thousand USD | -78.27% |
| 2005 Q3 | -20.3 Thousand USD | -98.46% |
| 2005 Q4 | -28.44 Thousand USD | -40.1% |
| 2005 FY | -67.96 Thousand USD | 61.17% |
| 2004 Q1 | -81.5 Thousand USD | 41.67% |
| 2004 Q2 | -51.79 Thousand USD | 36.45% |
| 2004 FY | -175.05 Thousand USD | 74.99% |
| 2004 Q4 | 2923.00 USD | 106.54% |
| 2004 Q3 | -44.67 Thousand USD | 13.76% |
| 2003 Q1 | -203.91 Thousand USD | 54.81% |
| 2003 Q2 | -186.64 Thousand USD | 8.47% |
| 2003 FY | -699.82 Thousand USD | -166.7% |
| 2003 Q4 | -139.73 Thousand USD | 17.57% |
| 2003 Q3 | -169.53 Thousand USD | 9.17% |
| 2002 Q4 | -451.18 Thousand USD | -771.25% |
| 2002 Q2 | 101.2 Thousand USD | 396.87% |
| 2002 Q1 | 20.36 Thousand USD | 112.32% |
| 2002 FY | -262.4 Thousand USD | 17.47% |
| 2002 Q3 | 67.21 Thousand USD | -33.58% |
| 2001 Q4 | -165.38 Thousand USD | -283.54% |
| 2001 Q1 | -141.1 Thousand USD | 57.37% |
| 2001 FY | -317.96 Thousand USD | 58.79% |
| 2001 Q3 | -43.12 Thousand USD | -36.32% |
| 2001 Q2 | -31.63 Thousand USD | 77.58% |
| 2000 Q1 | -176.53 Thousand USD | 0.0% |
| 2000 Q2 | -158.51 Thousand USD | 10.21% |
| 2000 FY | -771.54 Thousand USD | -8.72% |
| 2000 Q3 | -105.45 Thousand USD | 33.47% |
| 2000 Q4 | -331.04 Thousand USD | -213.92% |
| 1999 FY | -709.65 Thousand USD | -206.05% |
| 1998 FY | -231.87 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 100.0% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 100.0% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 100.0% |
| Nascent Biotech, Inc. | -2.08 Million USD | 100.0% |
| Rebus Holdings, Inc. | -1.02 Million USD | 100.0% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 100.0% |
| Qrons Inc. | -789.34 Thousand USD | 100.0% |
| Adynxx, Inc. | - USD | NaN% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 100.0% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 100.0% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 100.0% |
| Skye Bioscience, Inc. | -37.64 Million USD | 100.0% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 100.0% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 100.0% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 100.0% |
| SQZ Biotechnologies Company | -79.46 Million USD | 100.0% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 100.0% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 100.0% |
| Mesoblast Limited | -87.95 Million USD | 100.0% |
| Marizyme, Inc. | -65.34 Million USD | 100.0% |
| Genus plc | 7.9 Million USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 100.0% |
| Pharming Group N.V. | -10.54 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 100.0% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 100.0% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 100.0% |
| ContraFect Corporation | -65.15 Million USD | 100.0% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | NaN% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 100.0% |
| IMV Inc. | -36.48 Million USD | 100.0% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 100.0% |
| MultiCell Technologies, Inc. | -380.07 USD | 100.0% |
| ONE Bio Corp. | 8.67 Million USD | 100.0% |
| Accustem Sciences Inc. | -3.74 Million USD | 100.0% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 100.0% |
| Arno Therapeutics, Inc. | - USD | NaN% |
| EV Biologics, Inc. | -1.26 Million USD | 100.0% |
| Q BioMed Inc. | -2.05 Million USD | 100.0% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 100.0% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 100.0% |
| Biomind Labs Inc. | -1.21 Million USD | 100.0% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 100.0% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 100.0% |
| TetraLogic Pharmaceuticals Corporation | - USD | NaN% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 100.0% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 100.0% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | 100.0% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 100.0% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 100.0% |
| GB Sciences, Inc. | -1.36 Million USD | 100.0% |
| Alpha Cognition Inc. | -13.77 Million USD | 100.0% |
| HST Global, Inc. | -146.21 Thousand USD | 100.0% |
| CSL Limited | 2.64 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 100.0% |
| Halberd Corporation | -79.67 Thousand USD | 100.0% |
| Enzolytics Inc. | -2.17 Million USD | 100.0% |
| Agentix Corp. | -1.37 Million USD | 100.0% |
| Resverlogix Corp. | -3.61 Million USD | 100.0% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 100.0% |
| MetaStat, Inc. | - USD | NaN% |
| argenx SE | -295.05 Million USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 100.0% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 100.0% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 100.0% |
| GeneThera, Inc. | - USD | NaN% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 100.0% |
| AVAX Technologies, Inc. | -6.41 Million USD | 100.0% |
| Zenith Capital Corp. | -10.59 Million USD | 100.0% |
| Genscript Biotech Corporation | -95.47 Million USD | 100.0% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | 100.0% |
| Anthera Pharmaceuticals, Inc. | - USD | NaN% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 100.0% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | 100.0% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 100.0% |
| Kadimastem Ltd | -3.3 Million USD | 100.0% |
| Helix BioMedix, Inc. | -1.05 Million USD | 100.0% |
| VitaSpring Biomedical Co. Ltd. | - USD | NaN% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 100.0% |
| BioStem Technologies, Inc. | -8.48 Million USD | 100.0% |
| Oncology Pharma Inc. | - USD | NaN% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 100.0% |
| LadRx Corporation | 400.44 Thousand USD | 100.0% |
| Cell Source, Inc. | -5.32 Million USD | 100.0% |
| Regen BioPharma, Inc. | 1.02 Million USD | 100.0% |
| Regen BioPharma, Inc. | 1.02 Million USD | 100.0% |
| NovAccess Global Inc. | -4.76 Million USD | 100.0% |
| Affymax, Inc. | -14.42 Million USD | 100.0% |
| Itoco Inc. | -1.86 Million USD | 100.0% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 100.0% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 100.0% |
| Mobile Lads Corp. | -2.26 Million USD | 100.0% |
| CytoDyn Inc. | -49.84 Million USD | 100.0% |
| Claritas Pharmaceuticals, Inc. | - USD | NaN% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | 100.0% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 100.0% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 100.0% |
| SYBLEU INC | -180.3 Thousand USD | 100.0% |
| Advanced Proteome Therapeutics Corporation | - USD | NaN% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 100.0% |
| International Stem Cell Corporation | -131 Thousand USD | 100.0% |
| Bioxytran, Inc. | -4.28 Million USD | 100.0% |
| GlobeImmune, Inc. | - USD | NaN% |
| Predictive Technology Group, Inc. | - USD | NaN% |
| ProText Mobility, Inc. | -54.27 Thousand USD | 100.0% |
| Cardax, Inc. | - USD | NaN% |
| VG Life Sciences Inc. | -2.53 Million USD | 100.0% |
| Kaleido Biosciences, Inc. | - USD | NaN% |
| Advaxis, Inc. | -48.07 Million USD | 100.0% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 100.0% |
| Regnum Corp. | -780.88 Thousand USD | 100.0% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 100.0% |
| Neutra Corp. | -233.46 Thousand USD | 100.0% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 100.0% |
| PureTech Health plc | -65.69 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 100.0% |
| IXICO plc | -1.17 Million USD | 100.0% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 100.0% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 100.0% |
| CSL Limited | 2.64 Billion USD | 100.0% |
| Cellectis S.A. | -103.17 Million USD | 100.0% |